-
Mashup Score: 0
Findings from the EDGE-Gastric trial suggest potential for 2 novel agents in patients with gastroesophageal adenocarcinoma.
Source: www.docwirenews.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 0Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma - 7 month(s) ago
Analysis of a spectrum of subsolid pulmonary nodules by single-cell RNA sequencing provides insights into the immune regulation and cell–cell interactions in the tumor microenvironment during early lung tumor development.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma - 8 month(s) ago
Development of a Drosophila model mimicking genetic alterations in human pancreatic ductal adenocarcinoma provides a tool for genetic screening that identifies MEK and AURKB inhibition as a potential treatment strategy.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma - 8 month(s) ago
Development of a Drosophila model mimicking genetic alterations in human pancreatic ductal adenocarcinoma provides a tool for genetic screening that identifies MEK and AURKB inhibition as a potential treatment strategy.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma - 8 month(s) ago
Syk blockade induces macrophage polarization to an immunostimulatory phenotype, which enhances CD8+ T-cell responses and improves gemcitabine efficacy in pancreatic ductal adenocarcinoma, a clinically challenging malignancy.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pancreatic ductal #adenocarcinoma has a poor prognosis with a 5-year survival rate of only 11 percent. The study of #PancreaticCancer genomes has identified four key driver genes—KRAS, SMAD4, CDKN2A, and TP53—responsible for development of solid tumors: https://t.co/uiCtEw55QY https://t.co/AyBAo09SFt
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The Impact of Tumor-Infiltrating B Cells in Lung... : Oncology Times - 9 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - ASCO 2023: Phase II Trial Assesses Combination Strategies for Treating Gallbladder Adenocarcinoma - 10 month(s) ago
By: Joshua D. Madera, MD Posted: Wednesday, June 21, 2023 After resection of gallbladder cancer, both the use of combination therapy with gemcitabine plus cisplatin and capecitabine with chemoradiation therapy improved patients’ disease-free survival, according to the findings of the phase II GECCOR-GB trial, which…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Initial findings from Arm A1 of the phase 2 EDGE-Gastric trial suggest potential for 2 novel agents to improve outcomes in patients with advanced gastroesophageal #adenocarcinoma. Learn more: https://t.co/mSRIeAoif1 https://t.co/K8HLmqoNkw